Article Figures & Data
Figures
- Figure 1 Selection of the Studies Included in the Analysis
Study selection process according to the new 2020 update of the Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) statements.
- Figure 2 Comparison Between Multiple Sclerosis vs Healthy Controls
Forest plot of meta-analysis (with sensitivity analysis) (A) CHI3L1 levels in CSF in patients with MS vs healthy controls (HC); (B) subgroups analysis comparing CHI3L1 levels in CSF in HC vs relapsing-remitting + progressive forms (RRMS+PMS) and in HC vs RRMS only. Random-effects model was used. Outcomes are expressed as standardized mean difference (SMD) with 95% CI. Overall effect is expressed with Z score; heterogeneity is expressed with Tau and coefficients. Subgroup differences are expressed through score. The SMD of the studies excluded from the analysis compared in the forest plot as “not estimable.” (C) Standardization of absolute value of CSF levels of CHI3L1 with Z-scores extraction.
- Figure 3 Comparison Between Multiple Sclerosis vs Clinically Isolated Syndrome
- Figure 4 Comparison Between Relapsing-Remitting vs Progressive Multiple Sclerosis
Forest plot of meta-analysis showing CHI3L1 levels in CSF in patients with relapsing remitting MS (RRMS) vs progressive MS (PMS). Random-effects model was used. Overall effect is expressed with Z score; heterogeneity is expressed with Tau and coefficients. Subgroup differences are expressed through score. PPMS = primary progressive MS; SPMS = secondary progressive MS.
- Figure 5 Comparison Between Primary vs Secondary Progressive Multiple Sclerosis
Forest plot of meta-analysis (with sensitivity analysis) showing CHI3L1 levels in CSF in patients with primary progressive MS (PPMS) vs secondary progressive MS (SPMS). Random-effects model was used. Overall effect is expressed with Z score; heterogeneity is expressed with Tau and coefficients. The SMD of the studies excluded from the analysis compared in the forest plot as “not estimable.”
- Figure 6 Comparison Between Relapse vs Remission Stage of Disease
Forest plot of meta-analysis showing: (A) CHI3L1 levels in CSF in patients with acute relapse vs remission stage of the disease; (B) proportions of patients with gadolinium enhancing lesion (GD+) on MRI in those with higher vs lower CHI3L1 levels in CSF. To compare the proportions, the Mantel-Haenszel model was used. Outcomes are expressed as Odds-Ratio, with 95% CI. Random-effects model was used for all the analysis. Overall effect is expressed with Z score; heterogeneity is expressed with Tau and coefficients.
- Figure 7 Comparison Between Serum Levels of CHI3L1 Between Relapsing-Remitting Multiple Sclerosis vs Healthy Controls
Forest plot of meta-analysis showing CHI3L1 levels in serum in patients with relapsing-remitting MS (RRMS) vs healthy controls (HC). Random-effects model was used for all the analysis. Overall effect is expressed with Z score; heterogeneity is expressed with Tau and coefficients.
Tables
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.